Clinical efficacy analysis of Avatrombopag in thrombocytopenia associated with chronic liver disease
WEI Xun
QIN Xin-meng
MA Li
KANG Yi
Abstract：Objective To assess the safety and effect of Avatrombopag in real world chronic hepatosis related thrombocytopenia patients.Methods The data of patients with thrombocytopenia related to chronic liver disease who planned to undergo invasive operation and received Avatrombopag treatment in Henan Provincial People's Hospital from March 2021 to October 2023 were collected,and the changes in platelet count,blood transfusion and adverse reactions were recorded and analyzed.Results The overall response rate of Avatrombopag for Chronic hepatosis related thrombocytopenia was 82.0％;The baseline platelet level was(39.45±16.37)× 109/L,The median onset time was 7(5,14)d,The median peak time was 13(6,18)d,The peak platelet count was(123.65±12.22)×109/L,The platelet count increase was(83.79±27.5)× 109/L;9.0％of the patients received platelet transfusion,None of the patients had serious adverse events;The Avatrombopag efficacy was more significant at baseline platelets＜30×109/L(P＜0.05);Platelet count remained above baseline at 28 days of administration(P＜0.0001).Conclusion Avatrombopag can significantly improve the platelet count in Chronic hepatosis related thrombocytopenia patients and reduce the bleeding risk and platelet transfusion rate,without obvious serious adverse effects.
Keywords：chronic liver diseasethrombocytopeniaAvatrombopagclinical effectsafety
Publication Date：2024-07-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 567-570 )